Higher efficacy and reduced adverse reactions in neoadjuvant chemotherapy for breast cancer by using pegylated liposomal doxorubicin compared with pirarubicin

Higher efficacy and reduced adverse reactions in neoadjuvant chemotherapy for breast cancer by using pegylated liposomal doxorubicin compared with pirarubicin

Abstract The present study aimed to investigate the efficacy and toxicity of pegylated liposomal doxorubicin (PLD) in preoperative neoadjuvant chemotherapy for patients with breast cancer by comparing with conventional anthracycline. This study is a non-randomized controlled trial. Prospective analy...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Weifang Liu, Wei Chen, Xiuxiang Zhang, Peng Zhao, Zhimin Fan, Lirong Bi, Di Wu, Sijie Li, Ming Yang, Tong Fu, Dong Song, Bing Han, Gang Zhao, Ye Du, Aiping Shi
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/0142dbe839ec41b5aa9108e70487e916
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares